SLC12A2 and inflammatory bowel disease: A similar effect of the inhibitors targeted to CFTR, the K+ channel or NKCC1 was confirmed not only in the jejunal organoids that were established from the uninflamed mucosa of an IBD patient but also in organoids that were established from the healthy mucosa of a non-IBD patient (Fig. 5d).